Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3

FEBS Letters

Volumn 584, Issue 3, 2010, Pages 591-598

  Werk, Denise ^a   Wengel, Jesper ^b   Wengel, Suzy L ^c   Grunert, Hans Peter ^a   Zeichhardt, Heinz ^a   Kurreck, Jens ^d,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c RiboTask ApS ^*  (Denmark)

^d UNIVERSITY OF STUTTGART   (Germany)

^e TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Coxsackievirus; Locked nucleic acid; RNA interference; Small interfering RNAs; Unlocked nucleic acid

Indexed keywords

LOCKED NUCLEIC ACID; NUCLEIC ACID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNLOCKED NUCLEIC ACID;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; HEART DISEASE; NONHUMAN; NUCLEIC ACID STRUCTURE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; ENTEROVIRUS B, HUMAN; HEART; NUCLEIC ACIDS; RNA, SMALL INTERFERING; VERO CELLS;

COXSACKIEVIRUS;

EID: 74249105946     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.12.007     Document Type: Article

References (31)

1. Castanotto D., and Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457 (2009) 426-433
2. Kurreck J. RNA interference: from basic research to therapeutic applications. Angew. Chem., Int. Ed. Engl. 48 (2009) 1378-1398
3. Grimm D. Small silencing RNAs: state-of-the-art. Adv. Drug Deliv. Rev. 61 (2009) 672-703
4. Khvorova A., Reynolds A., and Jayasena S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell 115 (2003) 209-216
5. Schwarz D.S., Hutvagner G., Du T., Xu Z., Aronin N., and Zamore P.D. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115 (2003) 199-208
6. Grunweller A., and Hartmann R.K. Locked nucleic acid oligonucleotides: the next generation of antisense agents?. BioDrugs 21 (2007) 235-243
7. Veedu R.N., and Wengel J. Locked nucleic acid as a novel class of therapeutic agents. RNA Biol. 6 (2009) 321-323
8. Di Primo C., Rudloff I., Reigadas S., Arzumanov A.A., Gait M.J., and Toulme J.J. Systematic screening of LNA/2′-O-methyl chimeric derivatives of a TAR RNA aptamer. FEBS Lett. 581 (2007) 771-774
9. Elmen J., Thonberg H., Ljungberg K., Frieden M., Westergaard M., Xu Y., Wahren B., Liang Z., Orum H., Koch T., and Wahlestedt C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33 (2005) 439-447
10. Braasch D.A., Jensen S., Liu Y., Kaur K., Arar K., White M.A., and Corey D.R. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry (Moscow) 42 (2003) 7967-7975
11. Jensen T.B., Langkjaer N., and Wengel J. Unlocked nucleic acid (UNA) and UNA derivatives: thermal denaturation studies. Nucleic Acids Symp. Ser. (2008) 133-134
12. Langkjaer N., Pasternak A., and Wengel J. UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg. Med. Chem. 17 (2009) 5420-5425
13. Bramsen J.B., Laursen M.B., Nielsen A.F., Hansen T.B., Bus C., Langkjaer N., Babu B.R., Hojland T., Abramov M., Van Aerschot A., Odadzic D., Smicius R., Haas J., Andree C., Barman J., Wenska M., Srivastava P., Zhou C., Honcharenko D., Hess S., Muller E., Bobkov G.V., Mikhailov S.N., Fava E., Meyer T.F., Chattopadhyaya J., Zerial M., Engels J.W., Herdewijn P., Wengel J., and Kjems J. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 37 (2009) 2867-2881
14. Racaniello V.R. Picornaviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. fifth ed. (2007), Lippincott-Williams-Wilkins, Philadelphia 795-838
15. Cornell C.T., Perera R., Brunner J.E., and Semler B.L. Strand-specific RNA synthesis determinants in the RNA-dependent RNA polymerase of poliovirus. J. Virol. 78 (2004) 4397-4407
16. Haasnoot J., Westerhout E.M., and Berkhout B. RNA interference against viruses: strike and counterstrike. Nat. Biotechnol. 25 (2007) 1435-1443
17. Ahn J., Jun E.S., Lee H.S., Yoon S.Y., Kim D., Joo C.H., Kim Y.K., and Lee H. A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge. J. Virol. 79 (2005) 8620-8624
18. Lee H.S., Ahn J., Jee Y., Seo I.S., Jeon E.J., Jeon E.S., Joo C.H., Kim Y.K., and Lee H. Universal and mutation-resistant anti-enteroviral activity: potency of small interfering RNA complementary to the conserved cis-acting replication element within the enterovirus coding region. J. Gen. Virol. 88 (2007) 2003-2012
19. Schubert S., Grunert H.P., Zeichhardt H., Werk D., Erdmann V.A., and Kurreck J. Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs. J. Mol. Biol. 346 (2005) 457-465
20. Werk D., Schubert S., Lindig V., Grunert H.P., Zeichhardt H., Erdmann V.A., and Kurreck J. Developing an effective RNA interference strategy against a plus-strand RNA virus: silencing of coxsackievirus B3 and its cognate coxsackievirus-adenovirus receptor. Biol. Chem. 386 (2005) 857-863
21. Yuan J., Cheung P.K., Zhang H.M., Chau D., and Yang D. Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand. J. Virol. 79 (2005) 2151-2159
22. Fechner H., Sipo I., Westermann D., Pinkert S., Wang X., Suckau L., Kurreck J., Zeichhardt H., Muller O., Vetter R., Erdmann V., Tschope C., and Poller W. Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J. Mol. Med. 86 (2008) 987-997
23. Kim J.Y., Chung S.K., Hwang H.Y., Kim H., Kim J.H., Nam J.H., and Park S.I. Expression of short hairpin RNAs against the coxsackievirus B3 exerts potential antiviral effects in Cos-7 cells and in mice. Virus Res. 125 (2007) 9-13
24. Merl S., Michaelis C., Jaschke B., Vorpahl M., Seidl S., and Wessely R. Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. Circulation 111 (2005) 1583-1592
25. Schubert S., Rothe D., Werk D., Grunert H.P., Zeichhardt H., Erdmann V.A., and Kurreck J. Strand-specific silencing of a picornavirus by RNA interference. Evidence for the superiority of plus-strand specific siRNAs. Antiviral Res. 73 (2007) 197-205
26. Dutkiewicz M., Grunert H.P., Zeichhardt H., Lena S.W., Wengel J., and Kurreck J. Design of LNA-modified siRNAs against the highly structured 5′ UTR of coxsackievirus B3. FEBS Lett. 582 (2008) 3061-3066
27. Tomari Y., Matranga C., Haley B., Martinez N., and Zamore P.D. A protein sensor for siRNA asymmetry. Science 306 (2004) 1377-1380
28. Schubert S., Grunweller A., Erdmann V.A., and Kurreck J. Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. J. Mol. Biol. 348 (2005) 883-893
29. Overhoff M., Alken M., Far R.K., Lemaitre M., Lebleu B., Sczakiel G., and Robbins I. Local RNA target structure influences siRNA efficacy: a systematic global analysis. J. Mol. Biol. 348 (2005) 871-881
30. Westerhout E.M., and Berkhout B. A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res. 35 (2007) 4322-4330
31. Kenski, D.M., Cooper, A.J., Li, J.J., Willingham, A.T., Haringsma, H.J., Young, T.A., Kuklin, N.A., Jones, J.J., Cancilla, M.T., McMasters, D.R., Mathur, M., Sachs, A.B. and Flanagan, W.M. (in press) Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5′-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Res.